BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
PFA re-energizes afib market
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, August 31, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Ammax signs option agreement with Evopoint for ADC for solid tumors
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Ammax signs option agreement with Evopoint for ADC for solid tumors
Jan. 10, 2023
No Comments
Ammax Bio Inc. has entered into an exclusive option with Evopoint Biosciences Co. Ltd. for a worldwide license, excluding Greater China, for the development and commercialization of a novel antibody-drug conjugate (ADC) for treating solid tumors.
BioWorld Science
Cancer
Antibody-drug conjugate
Immuno-oncology